pharmaceuticals

Retatrutide: Lilly’s Diabetes Drug Shows Significant Weight Loss & Blood Sugar Control

by

Lilly’s Retatrutide: A New Era in Diabetes and Weight Management? Eli Lilly’s investigational drug, retatrutide, is generating significant buzz after demonstrating impressive results in a late-stage trial for Type 2 diabetes. The findings, released today, suggest a potential breakthrough in managing both blood sugar and weight – a historically challenging combination for individuals with the … Read more

It’s not all about drugs, we want to help, Novo Nordisk boss says

by

Novo Nordisk CEO Calls for Radical Shift in Australia’s Approach to Chronic Disease Australia faces a “health challenge of the century” – chronic disease, with obesity as a key driver. That’s the message delivered by Novo Nordisk CEO Mike Doustdar at the National Press Club in Canberra on March 16, 2026. But his address wasn’t … Read more

Scientists turn plastic waste into Parkinson’s drug levodopa using engineered bacteria

by

From Plastic Waste to Parkinson’s Treatment: A Revolution in Sustainable Pharma? A groundbreaking study published in Nature Sustainability details a remarkable feat of bioengineering: transforming discarded plastic into levodopa (L-DOPA), a crucial medication for managing Parkinson’s disease. Researchers have engineered Escherichia coli bacteria to “upcycle” poly(ethylene terephthalate) – commonly known as PET – into this … Read more

The Fugitive & Pharma: How STAT Would Cover a Real-Life Drug Scandal

by

The “Fugitive” Scenario: Pharma Scandals in the Age of Scrutiny The 1993 thriller “The Fugitive” – a staple for many, including STATus Report host Alex Hogan – presents a chillingly plausible scenario: a pharmaceutical giant knowingly pushing a dangerous drug to market. The film’s plot, centered around falsified clinical trial data for the drug Provasic … Read more

Cancer Immunotherapy: New Target Found on Tumor Cells

by

Cancer Immunotherapy: A New Target Emerges as Cells ‘Barf’ Proteins Researchers have identified a surprising location for a key protein, Src, on the surface of cancer cells – a place it shouldn’t be. This discovery, reported in Science, could unlock new avenues for immunotherapy, particularly for solid tumors, which have historically been hard to treat … Read more

Defining the limits of immunotherapy in early small-cell lung cancer

by

Immunotherapy Plateau? New Data Shifts Focus Back to Radiation in Small Cell Lung Cancer A recent international clinical trial, NRG-LU005, has delivered a nuanced message in the fight against limited-stage small cell lung cancer (LS-SCLC). While the addition of immunotherapy drug atezolizumab to standard chemoradiation didn’t significantly improve overall survival, a surprising trend emerged: twice-daily … Read more

Ron Johnson Investigates FDA Rejections of Rare Disease Treatments

by

FDA Under Scrutiny: A Potential Shift in Rare Disease Drug Approvals Senator Ron Johnson (R-Wis.) has launched an investigation into the Food and Drug Administration’s (FDA) rejections of treatments for rare diseases, signaling growing concern over the agency’s decision-making process. The senator is specifically requesting access to the complete response letters – official rejections – … Read more

FDA’s Vinay Prasad Resigns: A Controversial Exit Explained

by

FDA Vaccine Chief’s Exit Signals a Potential Shift in Regulatory Scrutiny The recent departure of Dr. Vinay Prasad, the Food and Drug Administration’s (FDA) vaccine chief, marks a potentially significant moment for the agency and the pharmaceutical industry. Prasad’s second exit from the FDA, confirmed on March 6, 2026, follows a period of controversial decisions … Read more

Reviva Pharmaceuticals Announces Major Share Consolidation Plan

by

Reviva, Pharmaceuticals 07.03.2026 – 01:28:22 | boerse-global.de Reviva Pharmaceuticals enacts a 1-for-20 reverse stock split to boost share price for Nasdaq compliance and attract institutional investors, effective March 9. Reviva Pharmaceuticals Holdings Inc. (RVPH) is implementing a 1-for-20 reverse stock split, effective at the market open on Monday, March 9. Navigating Reverse Stock Splits: A … Read more

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Inovio Pharmaceuticals Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action

by

Inovio Pharmaceuticals Investors Face Deadline in Securities Class Action Investors who purchased Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities between October 10, 2023, and December 26, 2025, may be eligible to participate in a securities class action lawsuit. A lead plaintiff deadline of April 7, 2026, has been set for those wishing to direct the litigation. … Read more

© 2026 Newsy Today. All rights reserved.


For contact, advertising, copyright, issues email: office@newsy-today.com

For contact, advertising, copyright, issues email: office@newsy-today.com